Scholarlink

<p>In recent years, targeted radionuclide therapy (TRNT) has been widely recognized as a significant approach for treating malignant tumors, progressively influencing treatment decisions and prognosis for cancer patients. Common therapeutic radionuclides primarily include those emitting alpha rays and those emitting beta rays. ²²⁵Ac, a commonly used alpha-emitting radionuclide, has demonstrated encouraging results in clinical trials. However, its scarcity and high single-treatment cost significantly limit its clinical application. Beta-emitting therapeutic radionuclides, such as Yttrium-90 (⁹⁰Y) and Lutetium-177 (¹⁷⁷Lu), are the most widely employed. Among these, [¹⁷⁷Lu]Lu -labeled targeted radiopharmaceuticals like [¹⁷⁷Lu]Lu-DOTA-TATE and [¹⁷⁷Lu]Lu-PSMA have demonstrated significant efficacy in treating neuroendocrine tumors and prostate cancer patients, respectively, receiving FDA approval for clinical use in 2018 and 2022. [¹⁷⁷Lu]Lu-labeled radiopharmaceuticals emit relatively low-energy beta particles (Eβav = 133&#xa0;keV) with limited tissue penetration depth (approximately 3&#xa0;mm). Even when patients exhibit high somatostatin receptor expression and initial favorable response to [¹⁷⁷Lu]Lu-based TRNT, some develop resistance, leading to disease progression. Therefore, identifying alternative therapeutic radionuclides may further enhance TRNT efficacy and improve patient outcomes. Terbium-161 ([¹⁶¹Tb]Tb), a lanthanide element belonging to the same family as ¹⁷⁷Lu, possesses excellent decay characteristics and chemical properties. It has garnered significant attention as a potential alternative nuclide to ¹⁷⁷Lu.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The potential and research progress of 161Tb-based targeted radionuclide therapy

  • 期刊论文

  • 发表日期：

    2025年12月21日

查看全文
  • Yang Ji,
  • Min Wang,
  • Zhihan Yao,
  • Jiao Ma,
  • Chunyin Zhang

摘要

In recent years, targeted radionuclide therapy (TRNT) has been widely recognized as a significant approach for treating malignant tumors, progressively influencing treatment decisions and prognosis for cancer patients. Common therapeutic radionuclides primarily include those emitting alpha rays and those emitting beta rays. ²²⁵Ac, a commonly used alpha-emitting radionuclide, has demonstrated encouraging results in clinical trials. However, its scarcity and high single-treatment cost significantly limit its clinical application. Beta-emitting therapeutic radionuclides, such as Yttrium-90 (⁹⁰Y) and Lutetium-177 (¹⁷⁷Lu), are the most widely employed. Among these, [¹⁷⁷Lu]Lu -labeled targeted radiopharmaceuticals like [¹⁷⁷Lu]Lu-DOTA-TATE and [¹⁷⁷Lu]Lu-PSMA have demonstrated significant efficacy in treating neuroendocrine tumors and prostate cancer patients, respectively, receiving FDA approval for clinical use in 2018 and 2022. [¹⁷⁷Lu]Lu-labeled radiopharmaceuticals emit relatively low-energy beta particles (Eβav = 133 keV) with limited tissue penetration depth (approximately 3 mm). Even when patients exhibit high somatostatin receptor expression and initial favorable response to [¹⁷⁷Lu]Lu-based TRNT, some develop resistance, leading to disease progression. Therefore, identifying alternative therapeutic radionuclides may further enhance TRNT efficacy and improve patient outcomes. Terbium-161 ([¹⁶¹Tb]Tb), a lanthanide element belonging to the same family as ¹⁷⁷Lu, possesses excellent decay characteristics and chemical properties. It has garnered significant attention as a potential alternative nuclide to ¹⁷⁷Lu.